Immunovant (IMVT) Net Equity Issued and Repurchased (2019 - 2025)

Immunovant (IMVT) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $450.0 million in Q1 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $450.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2026 was $450.0 million (down 13.54% YoY) and the FY2026 annual result came in at $544.2 million, up 20.93% from the prior year.
• Net Equity Issued and Repurchased improved to $450.0 million in Q1 2025, from $70.5 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $450.0 million in Q1 2025 to a low of -$254.0 million in Q1 2021.
• A 3-year average of $116.6 million and a median of $135.2 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 6.33% in 2021, down 6.33% in 2021.
• Tracing IMVT's Net Equity Issued and Repurchased over 3 years: stood at $200.0 million in 2021, then sank by 64.75% to $70.5 million in 2022, then soared by 538.3% to $450.0 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $450.0 million (Q1 2025), $70.5 million (Q4 2022), and $200.0 million (Q3 2021), per Business Quant data.